Novartis Leqvio Launch Lags As COVID-19 Hinders England Access Scheme
Swiss Giant Waiting For Moratorium To Be Lifted
Executive Summary
The CEO and head of pharma at Novartis have both cautioned against expectations of a lucrative launch for Leqvio, saying that a completely new approach to treating cholesterol lowering with a vaccine-like approach of administration twice a year will take time to get established in healthcare systems.
You may also be interested in...
A Look At Leqvio’s Lacklustre Launch
The Swiss major’s CFO Harry Kirsch told Scrip that US cardiologists are slowly but surely getting to grips with the 'buy-and-bill' reimbursement model for Leqvio, while EU sales are not going to grow significantly until cardiovascular outcomes data read out in a few years’ time.
Leqvio Launch Will Be Fundamental To Success Of New Novartis
Discussion of the launch trajectory for the twice-yearly cholesterol therapy dominated the marketing portion of Novartis’s investor event and the firm is confident the foundations have been laid to push strong sales growth by the second half of next year.
Can Novartis Break Back Into The US Top Five? It Is Going To Need Bigger Blockbusters
Novartis has led the sector in number of launches, but has failed to find a mega-blockbuster to lift its standing in the US – its CEO hopes new leaders can help turn that around.